IP Library Patent Application 17282474
Patent Application
App. No. 17/282,474

METHOD TO RESTORE OR IMPROVE COGNITIVE FUNCTIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/282,474
Abstract

The present invention relates to the field of memory and cognitive functions. Here the inventors show that memory stimulations induce autophagy in the mouse hippocampus, while local pharmacological and genetic modulations of hippocampal autophagy strongly influence memory acquisition. More, the inventors observe that hippocampal autophagy declines during aging and they find that restoring autophagy specifically in the hippocampus of aged mice, following autophagy inducers (such as TAT-Beclin-1), can significantly reverse age-related memory decline. Their results reveal a novel physiological role of autophagy in regulating hippocampal-dependent memory functions, and demonstrate the potential therapeutic benefits of modulating autophagy in order to prevent and/or reverse the deleterious effects of aging on cognitive function. The present invention relates to an activator of the autophagy for use in the restoration and/or improvement of cognitive functions in a subject in need thereof.

Claims (14)

1 . (canceled)

2 . (canceled)

3 . (canceled)

4 . (canceled)

5 . The method of claim 11 , wherein the activator is selected from the group consisting of Earle's balanced salt solution (EBSS), Brefeldin A, Thapsigargin, Tunicamycin, Rapamycin, CCI-779, RAD001, AP23576, Small molecule enhancers rapamycin (SMER), Trehalose, L-690,330, Carbamazepine, Valproic acid sodium salt, N-Acetyl-D-sphingosine (C2-ceramide), Penitrem A, Calpastatin, Xestospongin B, Akebia saponin, Amiodarone hydrochloride, ATG13, GF 109203X synthetic, GF 109203X hydrochloride, N-Hexanoyl-D-sphingosine, MRT68921 dihydrochloride, Niclosamide, Qc1, Rottlerin, STF-62247, Tamoxifen, Temsirolimus, ULK Active, Z36 and Hydroxycitrate.

6 . The method of claim 11 , wherein the activator is Beclin 1.

7 . The method of claim 11 , wherein the activator is a peptide comprising an amino acid sequence of formula (I) (SEQ ID NO: 2):

Xaa1-N-A-T-F-Xaa2-Xaa3-Xaa4-Xaa5,

wherein:

Xaa1, Xaa2, Xaa3, Xaa4 and Xaa5 are each an amino acid independently selected from the group consisting of Alanine (A), Arginine (R), Asparagine (N), Aspartic acid (D), Cysteine (C), Glutamic acid (E), Glutamine (Q), Glycine (G), Histidine (H), Isoleucine (I), Leucine (L), Lysine (K), Methionine (M), Phenylalanine (F), Proline (P), Serine (S), Threonine (T), Tryptophan (W), Tyrosine (Y), Valine (V), allyl glycine (AllylGly), norleucine, norvaline, biphenylalanine (Bip), citrulline (Cit), 4-guanidinophenylalanine (Phe(Gu)), homoarginine (hArg), homolysine (hLys), 2-naphtylalanine (2-Nal), ornithine (Orn) Of and pentafluorophenylalanine.

8 . The method of claim 7 wherein the activator is the peptide TAT-Beclin 1 of SEQ ID NO:37.

9 . (canceled)

10 . (canceled)

11 . A method of i) restoring and/or improving one or more cognitive functions, ii) treating a cognitive disease, iii) preventing or reversing the deleterious effects of aging on cognitive function, and/or iv) restoring and/or improving age-related memory decline or age-related memory loss in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an activator of autophagy.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE PROPERTY NUMBER 16930208 PREVIOUSLY RECORDED AT REEL: 060390 FRAME: 0122. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Jan 11, 2023
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 062387/0489 →
CHANGE OF NAME Recorded Jun 20, 2022
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 060390/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2022
From: OURY, FRANCK; CODOGNO, PATRICE
To: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE DE PARIS; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Reel/Frame 060087/0597 →